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Abstract: Calcium phosphate bioceramics are widely used in orthopedic and dental applications 
and porous scaffolds made of them are serious candidates in the field of bone tissue engineering. 
They have superior properties for the stimulation of bone formation and bone bonding, both 
related to the specific interactions of their surface with the extracellular fluids and cells, ie, ionic 
exchanges, superficial molecular rearrangement and cellular activity. 
Keywords: calcium phosphate, biomaterials, tissue engineering, osteoprogenitor cells, 
osteoconduction, osteoinduction
Introduction
Calcium phosphate bioceramics have a unique characteristic for bone substitution 
compared with other biomaterials. They have such compositional resemblance to bone 
mineral that they induce a biological response similar to the one generated during 
bone remodeling. Bone remodeling or renewal consists of the resorption of old bone 
mineral coupled with the formation of new bone. During resorption, the degradation 
products of calcium phosphate bioceramics (calcium and phosphate ions) are naturally 
metabolized and they do not induce abnormal calcium or phosphate levels in urine, 
serum, or organs (liver, skin, brain, heart, kidney, lung, and intestine) (den Hollander et 
al 1991). Calcium phosphate biomaterials are successfully used in cranio-maxillofacial, 
dental, and orthopedic surgery. They are of synthetic origin (obtained after aqueous 
precipitation or after sintering) or natural origin (freeze-dried or banked bone and 
derived coral hydroxyapatite), and they are used as bone fillers in the form of cement 
or granules. As they cannot replace as such the load-bearing functions of bone because 
of their lower mechanical properties, they are also successfully used as coatings on 
metallic hip and dental implants in clinics (Epinette and Manley 2004). Naturally porous 
calcium phosphates biomaterials have been selected as relevant scaffold candidates 
in bone tissue engineering (Kruyt et al 2004; Arinzeh et al 2005). Technically, several 
procedures have been developed to tailor the scaffolds, such as rapid prototyping 
(Wilson et al 2004), phase mixing (Li et al 2002), use of porogenic agents (Barralet 
et al 2002), or shape replication (Tancred et al 1998). In addition, by selecting and/or 
combining calcium phosphate phases, one can tailor the resorption kinetics, and also 
their stimulating effect on bone formation (Dhert et al 1991; Dhert et al 1993; Barrere 
et al 2003a; Rahbek et al 2004; Habibovic et al 2005b; Schopper et al 2005). 
In this review, we address the molecular and cellular, interactions that take place 
at the calcium phosphate surfaces and we correlate them with their relevance in bone 
regeneration.
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Bone
Bone is the component of the skeletal system that is involved 
in body protection, support, and motion. Bone is a protection 
and production site for specialized tissues such as the 
blood-forming system, ie, bone marrow. Heart, lungs, and 
other organs and structures in the chest are protected by the 
rib cage. The function of these organs involving motion, 
expansion, and contraction requires flexibility and elasticity 
of the protective rib cage. Bone supports structurally the 
mechanical action of soft tissues, like the contraction of 
muscles or expansion of lungs. Finally, it is a mineral 
reservoir, whereby endocrine systems regulate the level of 
calcium and phosphate ions in the circulating body fluids. 
Bone structure 
Bone macro- and microscopic structures are affected by 
genetic, metabolic, and mechanical factors. These intrinsic 
factors are the main cause of bone macrostructural diversity. 
For example, broad, flat plates, such as the scapula, anchor 
large muscle masses, whereas hollow and thick-walled tubes, 
such as the femur or radius, support weight. All bone consists 
of a basic double structure, the importance of which varies 
with the function. An external layer, or cortex, covers the 
bone; it is smooth, dense, and continuous. In the interior, 
cancellous bone is arranged in a network of intersecting plates 
and spicules varying in amount and enclosing spaces. These 
cavities are filled with blood vessels and marrow, either red, 
hematopoietic or yellow, adipose, its character varying with 
age and site. 
Microscopically, bone is a highly complex and specialized 
form of connective tissue. It is a mineralized tissue, which 
is composed of an organic matrix strengthened by deposits 
of calcium phosphate crystals; in other words bone is a 
natural composite material. The organic matrix is composed 
of collagen type I fibers (approximately 95%) and of 
proteoglycans and numerous non-collagenous proteins (5%). 
This organic matrix, calcified by calcium phosphate minerals, 
embeds bone cells, which participate in the maintenance 
and organization of bone, namely osteoprogenitor cells, 
osteoblasts, osteocytes, and osteoclasts. 
Mechanical properties of bone
The intimate blend of hard inorganic and resilient organic 
components results in excellent mechanical properties. For 
example, compact bone specimens have been found to have 
tensile strength in the range of 700 to 1400 kg/cm
2, and 
compressive strength in the range of 1400 to 2100 kg/cm
2. 
These values are within the same magnitude as for aluminum 
or mild steel, but bone is much lighter. The great strength 
of bone exists principally along its axis and hence roughly 
parallel both to the collagen fiber axis and to the long axis 
of mineral crystals. Although apparently stiff, bones exhibit 
a considerable degree of elasticity, which is important in the 
skeleton’s ability to withstand impact. Estimates of modulus 
of elasticity of bone samples are of the order of 420 to 
700 kg/cm
2, values very much less than steel, for example, 
indicating much greater elasticity of bone. 
Bone renewal 
Bone is a dynamic tissue. In the first year of life, the rate of 
turnover of the skeleton approaches 100% per year. This rate 
declines to about 10% per year in late childhood, and then 
usually continues at approximately this rate or more slowly 
throughout life, up to hundred years. After the completion 
of skeletal growth, bone turnover results primarily from 
remodeling: a coordinated cycle of tissue resorption and 
formation over extensive regions of bone and prolonged 
periods. Throughout life, physiological remodeling, removal, 
and replacement of bone, at roughly the same location, occur 
without affecting the shape or density of the bone, through 
a sequence of events that include (i) osteoclasts activation, 
(ii) resorption of bone, (iii) osteoblasts activation, and (iv) 
formation of new bone at the site of resorption (Buckwalter 
et al 1996). Owing to these remodeling properties, defects 
and fractures are easily repaired up to sizes called critical 
defects, defined as defects of a size that will not heal during 
the lifetime of the animal (Schmitz and Hollinger 1986). For 
larger defects, human interventions are necessary in order to 
help or stimulate the healing.
Bone mineral
Bone mineral, or enamel (biological apatite) have structure 
close to a type AB carbonated calcium phosphate apatitic 
structure more or less deficient, which can be tentatively 
represented by the formula (Rey 1990) 
Ca8.3 1.7(PO4)4.3(CO3)1(HPO4)0.7(OH,CO3)0.3 1.7
= vacancy
However, bone mineral apatite contains non-apatitic 
carbonate and phosphate groups, which are, structurally and 
physically, unstable and very reactive. This high reactivity 
provides certain physicochemical, biological, functional, and 
chemical features important in the formation and dissolution 
of the crystals in biological tissues. Furthermore, bone 
contains minor or trace elements, which are not indicated international Journal of Nanomedicine 2006:1(3) 319
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in the above formula, and which are difficult to attribute to 
either the mineral phase or the organic matrix (Rey 1990). In 
bone and other mineralized tissues, the mineral crystals are 
formed of thin plates of irregular shapes. Their sizes range 
in length from 20 Å for the smallest particles, to 1100 Å for 
the largest particles (Moradianoldak et al 1991; Kim et al 
1995). These bone crystals expose a very large surface area 
to the extracellular fluids, which is critically important for 
the rapid exchange of ions with these fluids. 
Bone mineral starts to nucleate into the holes and 
pores present in the collagen fibrils (Glimcher 1987). This 
heterogeneous nucleation is catalyzed by the presence 
of phosphated esters groups (Glimcher et al 1984) and 
carboxylate groups (Rhee et al 2000) present in the collagen 
fibrils. Thereafter, the growth, or mineralization, takes place 
along the collagen fibrils, eventually interconnecting all of 
the collagen fibrils.  
The nature of the primary mineral phase formed prior 
to mature bone mineral apatite remains controversial. 
According to Posner, bone mineral apatite derives from 
calcium phosphate clusters (Ca9(PO4)6) packing randomly 
with interfacial water to form amorphous calcium phosphate 
precursor (Posner 1985). This theory is supported by the 
presence of several calcium phosphate growth inhibitors such 
as magnesium that stabilize the amorphous state. However, 
dicalcium phosphate (DCPD) (Grynpas et al 1984; Roberts 
et al 1992) and octacalcium phosphate (OCP) phases have 
been also proposed as bone mineral precursors because 
of the partial similarities, especially between apatite and 
OCP (Brown et al 1987). DCDP and OCP are kinetically 
favored compared with apatitic phases, supporting their 
role as precursors in bone apatite formation (Nancollas and 
Wu 2000). However, Kuhn et al (2000) have shown that the 
apatitic phase seems to be the largely dominant one compared 
with other possible transient phases even at the earliest stages 
of mineralization.
Biologically relevant calcium 
phosphates 
Synthetic calcium phosphates
Calcium phosphates, or more accurately calcium ortho-
phosphates, are salts of orthophosphoric acid (H3PO4), and 
thus can form compounds that contain H2PO4
–, HPO3
2– or 
PO4
3–. The calcium phosphate salts constitute a wide 
group of compounds (Elliot 1994). Table 1 summarizes 
the chemical name, the formula, the abbreviation, and 
the calcium to phosphorus ratio (Ca/P) of some calcium 
phosphate compounds. Calcium phosphate salts vary by their 
composition and their crystal structures, leading to specific 
physicochemical properties. 
Apatites
Stoichiometric hydroxyapatite (HA) belongs to the general 
and wide apatitic group, represented by the formula:
Me10(XO4)6Y2
Where Me is a divalent metal (Ca
2+, Sr
2+, Ba
2+, Pb
2+ …), 
XO4 is a trivalent anion (PO4
3–, AsO4
3–, VO4
3– …), and Y is 
a monovalent anion (F
– Cl
–, Br
–, I
–, OH
–…). Apatitic crystal 
structure has usually a hexagonal lattice, having a strong ability 
to form solid solutions, and to accept numerous substitutions. 
The structure of biological apatites, namely bone 
mineral, dentine, or tooth enamel, is far different from 
stoichiometric HA because of numerous substitutions (i) 
by hydrogenophosphate (HPO4
2–) of XO4 groups and (ii) 
by carbonate (CO3
2–) of Y2 and XO4 groups. In addition, 
Rey (1990) has shown that bone mineral apatites contains 
non-apatitic carbonate and phosphate groups, which are, 
structurally and physically, unstable and very reactive (Rey 
1990). This high reactivity provides certain physicochemical, 
biological, functional, and chemical features important in 
the formation and dissolution of the crystals in biological 
tissues. The substitutions affect the apatitic lattice parameters: 
the crystal size is decreased, and thereby the surface area 
is increased compared with stoichiometric HA (Legeros 
1991). Biological apatites contain various trace elements 
from intrinsic origins, for example, fluoride is present in 
dental apatite and confers to enamel its low dissolution 
properties to resist acidic attacks; or from extrinsic origins, 
for example, water pollution is a straightforward intake of 
trace elements for bone due to its high hosting capacity 
(Cazalbou et al 2004). In addition these trace elements present 
in extracellular fluids and in bone apatite may have a specific 
role on bone quality and health. Table 2 presents the trace 
elements known to have an effect on bone.
Table 1  Main biologically relevant calcium phosphate salts
Name  Formula  Abbreviation  Ca/P
Dicalcium phosphate   CaHPO4  DCPA  1.00 
anhydrate or monetite
Dicalcium phosphate   CaHPO4.2H2O  DCPD  1.00 
dihydrate or brushite
Octacalcium phosphate  Ca8(PO4)4(HPO4)2.5H2O  OCP  1.33
Tricalcium phosphate  Ca3(PO4)2  TCP  1.50
Hydroxyapatite  Ca10(PO4)6(OH)2  HA  1.67international Journal of Nanomedicine 2006:1(3) 320
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HA-based biomaterials have been until now the most 
abundant materials used in modern bone substitution 
(Epinette and Manley 2004). Clinically, apatitic biomaterials 
are widely used in the form sintered macroporous granules, 
cement in non-load-bearing applications, and in the form or 
coatings on metallic prostheses. More recently, carbonated 
apatite biomaterials have been developed as their composition 
and structure characterics are closer to those of bone mineral. 
But their superiority compared with pure apatite is not yet 
proven. 
Tricalcium phosphate 
Two major distinct phases of anhydrous tricalcium phosphate 
(TCP) crystals exist: α-TCP and β-TCP phases. The α-TCP 
crystallizes in the monoclinic space group, and β-TCP 
crystallizes in the rhombohedral space group. Despite their 
similar chemical composition, their different crystallographic 
features confer different resorption features: α-TCP is more 
soluble than β-TCP, and it is obtained after heating the β-TCP 
to more than 1170ºC. Clinically, α-TCP is a major reagent in 
the composition of cements as they hydrolyze into apatitic 
structures, but it is also sold under the form of powder, blocks, 
or granules, like β-TCP. In pre-clinical studies, TCP coatings 
on hip prostheses have been compared with HA coatings for 
bone formation and bone fixation (Dhert et al 1991, 1993).
Dicalcium phosphate dihydrate 
DCPD crystals (CaHPO4.2H2O) are monoclinic. There 
are four formulas per unit cell with an asymmetric unit 
CaHPO4.2H2O. DCPD crystals are one of the most soluble   
of the calcium phosphate salts, and are the most stable at 
pH=5.0. They can be the end product of brushite calcium 
phosphate cement. However, in clinical applications, DCPD 
crystals are used as an initial components for bone cements. 
Octacalcium phosphate 
Octacalcium phosphate (OCP, Ca8H2(PO4)6.5H2O) crystals 
are triclinic and they consist of alternating “apatite layers” 
(arrangement of calcium and phosphate groups similar to that 
of apatite) and “hydrated layers”. These two layers are linked 
to each other by Van der Walls and hydrogen bonds. OCP 
often occurs as a transient intermediate in the precipitation 
of the thermodynamically more stable HA and biological 
apatites. The close relationship between OCP and HA has 
been used to explain the incorporation (via hydrolysis) of 
impurities, particularly carbonate, magnesium, and sodium 
ions, and hence the non-stoichiometry of precipitated 
apatites (Legeros 1991). OCP is biocompatible, resorbable, 
and osteoconductive in the form of compacted powder or in 
the form of biomimetic coating (Barrere et al 1999, 2003a; 
Sasano et al 1999). In goat muscles, biomimetic OCP-coated 
Table 2  Selection of some trace elements having an effect on bone as such or in calcium phosphate biomaterials
Trace element  Mechanism of action    Evidences in combination with calcium  
phosphates bioceramics
Copper  Cross-linking of collagen and elastin;  No
  increasing bone strength  
  (Hunt 1998; Lowe et al 2002) 
Zinc  Stimulating osteoblastic activity in vitro;   reducing bone loss at the zinc-containing biomaterial 
  inhibiting bone resorption in vivo   (Kawamura et al 2003) 
  (Lowe et al 2002) 
Manganese  Stimulating alkaline phosphatase activity   No 
  in vitro (Leone et al 1995), and in vivo 
  (Pabbruwe et al 2004)
Fluoride  Stimulating alkaline phosphatase activity   Stabilizing bone bonding 
  increasing of bone mass (Modrowski et al 1992)   reducing biomaterial’s resorption (Dhert et al 1991, 1993)
Strontium  increasing bone mass: stimulating bone formation   No 
  and reducing bone resorption (Marie 2005)
Lithium  Stimulating human mesenchymal stem cells proliferation   No 
  (de Boer et al 2004)
Borate  Possibly interacting with mineral and vitamin D metabolism  No 
  (Hunt 1998)
Silicate  Stimulating extracellular matrix formation and mineralization  Stimulating bone remodeling (Porter et al 2004b) 
  (Carlisle 1988)international Journal of Nanomedicine 2006:1(3) 321
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porous materials were found to be osteoinductive (Barrere 
et al 2003a). However these materials have not been used 
clinically.
Amorphous calcium phosphates
Amorphous calcium phosphates vary widely in composition 
because of the possible insertion of several secondary ions. 
They are characterized by the broad X-ray diffraction bumps, 
and by infrared mono-component PO4 bands. The basic 
structure unit of amorphous calcium phosphates is a cluster 
of ions comprising Ca9(PO4)6 packed with interfacial water 
to form bigger entities. Amorphous calcium phosphates are 
the most soluble calcium phosphate salts; they are used as 
initial components of some cement.
Biphasic calcium phosphate
Biphasic calcium phosphate (BCP) is a mixture of two 
different calcium phosphate phases: the sparingly soluble 
HA and highly soluble tricalcium phosphate at different 
ratios. BCPs are obtained by sintering of deficient apatites   
(Ca10-xMx(PO4)6-y(HPO4)y(OH)2, Ca/P<1.67) at or above 
700°C according to the following reaction (Legeros et al 
2003):
Ca10-xMx(PO4)6-y(HPO4)y(OH)2 → Ca10(PO4)6(OH)2 + 
Ca3(PO4)2
The combination these two different calcium phosphate 
phases with different solubility in one biomaterial allows 
its degradation kinetics to be tuned in vitro and in vivo. 
Clinically, BCPs are used as bone fillers. 
Stability of calcium phosphates
Thermal stability
We present here a summary on the thermal transformations 
behavior, extensively developed by Elliot (Elliot 1994).
TCP and HA are the only calcium phosphate salts fully 
stable up to 1000°C. For TCP, up to 1125ºC, β-TCP is the 
most stable phase, whereas above this and up to 1430ºC α-
TCP phase is the most stable. For stoichiometric HA, above 
1000ºC, some hydroxyl groups may condense to produce 
water following the reaction:
Ca10(PO4)6(OH)2 ↔ Ca10(PO4)6O   + H2O
= vacancy
DCPD, OCP, carbonates, and/or deficient apatite are 
subjected to thermal transformations: 
The water-containing phases such as DCPD or OCP 
dehydrate at approximately 180°C. The HPO4 containing 
calcium phosphate phases such as deficient apatite, OCP 
or DCPD sustain a condensation resulting in the formation 
of pyrophosphates ions (P2O7
4–) at approximately 300°C 
according to the reaction: 
2HPO4
2– → P2O7
4– + H2O
Depending on the substitution mode, the thermal treatment 
of carbonated apatite may lead to the release of CO2 gas with 
subsequent rearrangements. 
As a result of a thermal treatment, carbonated and/or 
deficient apatite, OCP, and DCPD will transform in a mixture 
of sub-products: pyrophosphate, HA, and TCP. 
Stability in physiological systems
The formation, dissolution, and transformation of calcium 
phosphates depend on the nature of the calcium phosphate 
body (particle size, crystallographic features, density) and the 
nature of the solution (composition, pH, temperature).
Most of calcium phosphates are sparingly soluble in 
water, and some are very insoluble, but all dissolve in 
acids. Their solubility, defined as the amount of dissolved 
solute contained in a saturated solution when particles of 
solute are continually passing into solution (dissolving) 
while other particles are returning to the solid solute phase 
(growth) at exactly the same rate (Wu and Nancollas 1998), 
decreases with the increase in temperature and in pH (de 
Groot 1983). 
Each calcium phosphate phase possesses its own 
thermodynamical solubility. For example, at pH=7 and 37ºC, 
HA is the most stable phase, followed by TCP, OCP, and   
finally DCPD. However, these thermodynamical consider-
ations are under equilibrium conditions, and therefore they 
do not take into account kinetics that dictates the formation 
of one or the other phase under dynamic conditions. 
The second important factor in the stability of the calcium 
phosphates is the characteristics of the solution in which these 
salts are formed or placed, namely the solution supersatur-
ation in free calcium and phosphates ions (Tang et al 2001). 
At a given pH and temperature, a free calcium and phosphate 
ion containing solution can be categorized in three different   
states: (i) the stable (undersaturated) zone, where crystalliza-
tion is impossible, (ii) the metastable zone (supersaturated), 
where spontaneous crystallization of calcium phosphate salt 
is improbable, although the concentrations are higher than 
the ones corresponding to the salt solubility. If a crystal seed 
were placed in such a metastable solution, growth would 
occur on the seed; (iii) the unstable or labile (supersaturated) 
zone, where spontaneous crystallization of calcium 
phosphate is probable, but not inevitable (Mullin 1993). international Journal of Nanomedicine 2006:1(3) 322
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Extracellular fluids that are supersaturated for calcium 
and phosphate may induce the nucleation and growth of new 
calcium phosphate crystals.  
Biological milieus
In vivo, the interactions between the implant and its 
“biological surrounding” are highly complex due to the 
non-equilibrium conditions and due to the undefined 
amount of compounds playing a role in these interactions. 
Dhert et al (1998) addressed the kinetic of the early events 
taking place within the first month at the interface between 
calcium phosphate-coated implants in a press fit model, 
ie, implant and defect dimensions are equal, implicating a 
maximum contact between the hosting bone tissue and the 
biomaterial. Regardless of the nature of the biomaterial, its 
biological surrounding evolves with time. In the first 3 days, 
blood will have invaded all of the empty spaces between the 
original bone and the implant. Thereafter, at the end of the 
first week of implantation, callus and mesenchymal tissues 
will have entirely replaced blood while host bone resorption 
has started. Finally, between the second and fourth week of 
implantation, callus, mesenchymal tissues, and host bone 
will have gradually disappeared in favor of newly formed 
bone while bone remodeling takes place (Dhert et al 1998). 
In a nutshell, components of biological fluids and cells will 
interact with the biomaterial. The biomaterials features can 
affect the molecular and cellular interactions at their surface 
and consequently can affect the process of bone formation.
The molecular components
The body can be divided into two major aqueous compart-
ments: 2/3 of intracellular fluid within cells, and 1/3 of 
extracellular fluid. The extracellular fluid is divided into 
smaller compartments that are distinguished by different 
locations and different kinetic characteristics: (i) the 
interstitial fluids lie in the interstices of all body tissues 
that bathes all the cells in the body and is the link between 
the intracellular fluid and the intravascular compartment. 
Oxygen, nutrients, wastes, and chemical messengers all pass 
through the interstitial fluid; (ii) the plasma is the only major 
fluid compartment that exists as a real fluid collection all 
in one location. It differs from interstitial fluid in its much 
higher protein content and its high bulk flow (transport 
function). Plasma is the liquid in which red blood cells and 
white blood cells are suspended. The water of the plasma 
is freely exchangeable with that of body cells and other 
extracellular fluids and is available to maintain the normal
state of hydration of all tissues; (iii) the transcellular fluid 
is a small compartment that represents all those body fluids 
which are formed from the transport activities of cells; (iv) 
bone and dense connective tissues represent 15% of body 
water (intracellular:extracellular, 55:45). This water is 
mobilized much more slowly than the other components of 
the extracellular fluids. Extracellular fluids are composed of 
water-soluble molecules: organic (amino acids, sugars, fatty 
acids, coenzymes, vitamins, hormones, neurotransmitters) 
and inorganic (calcium, phosphates, potassium, carbonate, 
sulfate, magnesium, chloride, sodium, copper, zinc) 
compounds as well as the waste products from the cellular 
metabolism. 
The cellular components
As bone formation takes place in an organism during 
embryonic development, growth remodeling, and fracture 
healing, and after ectopic implantation of osteoinductive 
matrixes, a large reservoir of cells in the body is capable of 
osteogenesis throughout life (Aubin 2001). Although the 
biomaterials are subjected to numerous cellular interactions   
of diverse origin in vivo, we will consider only the cells 
that are related most directly to bone formation and 
regeneration.
The osteoblasts
Osteoblasts are derived from pluripotential mesenchymal 
stem cells that have the capacity to differentiate into 
various lineages. Mature osteoblasts are non-migratory, 
highly differentiated cells that can differ substantially in 
their properties depending on their stage of development. 
Their function and phenotype vary and four categories 
of cells can be described. First, the active osteoblasts 
are cuboidal in shape, mononuclear and they are rich in 
alkaline phosphatase activity. They synthesize and secrete 
collagen type I and glycoproteins (osteopontin, osteocalcin), 
cytokines, and growth factors into a region of unmineralized 
matrix (osteoid) between the cell body and the mineralized 
matrix (Kartsogiannis and Ng 2004). Osteoblasts produce 
also calcium phosphate minerals extra- and intracellularly 
within vesicles (Annaz et al 2004b). Second, osteocytes are 
mature osteoblasts which have become trapped within the 
bone matrix and are responsible for its maintenance. Third, 
bone-lining cells are found along the bone surfaces that are 
undergoing neither bone formation nor resorption. Finally, 
inactive osteoblasts are elongated cells, undistinguishable 
morphologically from the bone-lining cells. international Journal of Nanomedicine 2006:1(3) 323
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The osteoclasts
Osteoclasts are derived from hematopoietic stem cells that 
differentiate along the monocyte–macrophage lineage. 
They are responsible for bone resorption by acidification 
of bone mineral leading to its dissolution and by enzymatic 
degradation of demineralized extracellular bone matrix. 
The mature osteoclast is a functionally polarized cell that 
attaches via its apical pole to the mineralized bone matrix by 
forming a tight ring-like zone of adhesion, the sealing zone. 
This attachment involves the specific interaction between the 
cell membrane and some bone matrix proteins via integrins 
(transmembrane adhesion proteins mediating cell–substratum 
and cell–cell interactions). In the resorbing compartment, 
situated under the cell and delimited by the sealing zone, 
osteoclasts generate a milieu acidification resulting in the 
dissolution of bone mineral. This osteoclastic acidification 
is mediated by the action of carbonate anhydrase that 
produces carbon dioxide, water, and protons that are extruded 
across the cell membrane into the resorbing compartment 
(Kartsogiannis and Ng 2004). 
The mesenchymal stem cells and osteoprogenitor 
cells
Adult mesenchymal stem cells can be isolated from bone 
marrow, adipose tissues, or amniotic membrane. Mesenchymal 
stem cells are, by definition, of self-renewal capacity and able 
to repopulate all the appropriate differentiation lineages. They 
are multipotent cells that can differentiate into osteoblastic, 
myoblastic, adipocytic, chondrocytic, endothelial, and 
neurogenic lineage through a multi-step differentiation 
sequence as follows: proliferation, commitment, lineage 
progression, maturation, and differentiation. For the 
osteogenic lineage, mesenchymal stem cells sustain 
a cascade of differentiation steps as described by the 
following sequence: Mesenchymal stem cell → immature 
osteoprogenitor → mature osteoprogenitor → preosteoblast 
→ mature osteoblast → osteocyte or lining cells or apoptosis. 
The later the differentiation stage, the lower the cell self-
renewal and proliferation capacity (Aubin 2001). In bone 
marrow, osteoprogenitor cells represent a very small 
percentage (eg <0.005%) of nucleated cell types in healthy 
adult bone (Block 2005). Embryonic stem cells are also a 
potential source due to their pluripotentiallity and therefore 
their ability to differentiate into osteogenic lineage.  
Osteoprogenitor–stem cell differentiation is controlled by 
the “osteogenic mastergene” Cbfa1/Osf2 that intervenes in 
skeleton and tooth mineralization (Sodek and Cheifetz 2001). 
The differentiating osteoprogenitor cells express several 
bone matrix macromolecules, namely alkaline phosphatase, 
collagene type I, Cbfa1, bone sialoprotein, osteocalcin, and 
osteopontin (Sodek and Cheifetz 2001). 
Biological events at the calcium 
phosphate substrates 
ionic exchanges at calcium phosphate 
surfaces
Physico-chemically, calcium phosphate surfaces sustain 
dissolution–reprecipitation cascades as the result of 
exchanges at a solid–liquid interface in supersaturated 
conditions. In biological systems, this physico-chemical 
phenomenon is the result of a multi-component dynamic 
process involving ions and proteins. 
In terms of surface reactivity, ionic transfers occur from 
the solid phase to the aqueous liquid via surface hydration of 
calcium, inorganic phosphate species, and possible impurities 
like carbonate, fluoride, or chloride present in the biomaterial. 
Under physiological conditions, this dissolution process is 
highly dependent on the nature of the calcium phosphate 
substrate (Okazaki et al 1982; Dhert et al 1993; Ducheyne et 
al 1993; Radin and Ducheyne 1993; Christoffersen et al 1997; 
Doi et al 1999; Barrere et al 2003b), and on the composition 
and supersaturation of the environment in vitro (Hyakuna 
et al 1990; Raynaud et al 1998; Tang et al 2001), or the 
implantation site in vivo (Daculsi et al 1990; Barralet et al 
2000). Ionic transfers occur also from the surrounding fluids 
to the calcium phosphate substrate in vitro and in vivo, as 
illustrated by the formation of carbonated apatite nanocrystals 
as a result of surface transformation (Heughebaert et al 1988; 
Daculsi et al 1989, 1990; Johnsson et al 1991; de Bruijn et 
al 1992a; Radin and Ducheyne 1993; Barrere et al 2003b). 
The presence of magnesium and carbonate contributes to the 
formation of a poorly crystallized carbonated apatite that has 
similar features to the bone mineral phase (Furedi-Milhofer 
et al 1976; Legeros 1991; Elliot 1994). In the presence of 
proteins, this newly formed mineral phase is also associated 
with organic compounds (Heughebaert et al 1988; de Bruijn 
et al 1995; Barrere et al 2003b). This phase transformation 
occurs for all of the calcium phosphate bioceramics, even 
the stable apatitic structures, since they have a strong ability 
to adapt to their environment by hosting foreign ions and 
subsequently to sustain atomic rearrangements (Cazalbou 
et al 2004). However, crystalline hydroxyapatitic substrates 
are often too stable to transform. 
The result of these ionic exchanges favoring either phase 
transformation or dissolution follows the thermodynamical international Journal of Nanomedicine 2006:1(3) 324
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stability order, ie HA>TCP>OCP>DCPD from the least 
soluble to the most soluble. This surface reactivity has pivotal 
implications in the biological relevance of calcium phosphate 
bioceramics and will be discussed further later in this review. 
However, for a given calcium phosphate phase, the crystalline 
feature, eg, the presence of defaults in the crystal lattice 
or the decrease of crystal size, accelerates the dissolution. 
Eventually amorphous biomaterials dissolve faster than 
crystalline ones (Legeros 1991; de Bruijn et al 1992b; Barrere 
et al 2000). In addition, the presence of some additives of 
mineral origins within the calcium phosphate structure can 
affect the crystal lattice, and therefore can accelerate the 
dissolution, eg carbonate, silicate, or strontium in HA. On 
the other hand, some additives reduce in vitro and in vivo the 
dissolution process, eg fluoride in HA, magnesium or zinc 
in beta-TCP (Okazaki et al 1982; Legeros 1991; Dhert et al 
1993; Elliot 1994; Christoffersen et al 1997; Ito et al 2002; 
Porter et al 2004a). The incorporation of proteins into calcium 
phosphate can also affect the dissolution kinetics (Liu et al 
2003). Last but not least, micro- and macroporosity play an 
important role in the physicochemical dissolution process of 
calcium phosphates. The larger the exposed surface to the 
environment, the faster the biomaterial dissolves, simply 
because larger quantities of exchanges can take place (Radin 
and Ducheyne 1994). 
The proteins from the surrounding fluids are also 
involved in the ionic exchange mechanisms as observed in 
vitro. Their interaction with calcium phosphate substrates 
depend on the bioceramics characteristics (such as phase, 
crystallinity, composition, texture) (Sharpe et al 1997; 
El-Ghannam et al 1999; Rouahi et al 2006) and on the 
protein’s features (such as conformation, isoelectric point, 
composition), their concentration, and whether they act in 
solution or on substrates (Johnsson et al 1991; Hunter et al 
1996; Koutsopoulos and Dalas 2000; Combes and Rey 2002; 
Ofir et al 2004). Firstly, in suspension, proteins can inhibit or 
support calcium phosphate nucleation and growth (Johnsson 
et al 1991; Hunter et al 1996; Boskey and Paschalis 2001). 
For phosphorylated proteins, such as collagen, ostepontin, 
osteonectin, bone sialoprotein, or ostecalcin, phosphorylated 
entities have demonstrated their ability to nucleate and grow 
calcium phosphate crystals (Boskey and Paschalis 2001). 
However, not all of the phosphorylated proteins induce 
calcium phosphate formation; osteopontin especially is a 
strong crystallization inhibitor (Hunter et al 1996) . Secondly, 
when proteins adsorb onto calcium phosphate substrates, their 
charge, their concentration, and the presence of calcium in 
the surrounding fluids influence the surface-coverage kinetics 
and pattern that can evolve with time (Kawasaki et al 2003). 
These adsorbed proteins can thereafter influence the new 
formation of calcium phosphate crystals by blocking or 
not blocking the substrate’s nucleation sites (Koutsopoulos 
and Dalas 2000; Combes and Rey 2002; Ofir et al 2004), 
irrespective of the protein’s isoelectric point (Ofir et al 2004). 
These results obtained from in vitro experiments differ 
strongly from in vivo experiments, as hundreds of proteins 
are present in biological fluids, and their global effect on 
calcium phosphate reactivity is insufficiently understood. It 
is, however, clear that they play a significant role in the ionic 
exchanges and their subsequent effect on their biological 
activity, since proteins are detected in close association 
with the nanocrystalline carbonated apatite formed on the 
surface of calcium phosphate bioceramics in vitro and 
in vivo (Heughebaert et al 1988; Johnsson et al 1991; de 
Bruijn et al 1992b; de Bruijn et al 1994b; Radin et al 1998; 
Barrere et al 2003b). Consequently, the nature, quantity, and 
conformation of these proteins at the biomaterial surface 
will determine the cellular activity (El-Ghannam et al 1999; 
Rouahi et al 2006). 
Cellular interactions with calcium 
phosphate surfaces
In general, cell–biomaterial interactions depend on surface 
characteristics such as topography, chemistry, and surface 
physics. As mentioned above, surface characteristics 
determine the ionic exchange dynamics and the protein 
adsorption. They also affect the cellular activity, namely their 
attachment, proliferation, and differentiation.
Calcium phosphates – osteoblasts and 
osteoprogenitor cells
In vitro, cell–biomaterial interactions are assayed by primary 
osteoblasts, osteosarcoma cell lines, and mesenchymal–
osteoprogenitor cells issued from bone marrow. More and 
more research currently addresses the interaction between 
mesenchymal stem–progenitor cells and scaffolds, as these 
cells participate at the early stage of new bone tissue formation 
in vivo (Dhert et al 1998; Davies and Hosseini 2001; Devlin 
and Sloan 2002). In contrast with differentiated osteoblasts, 
osteoprogenitor cells are migratory, highly proliferative 
cells and they have a greater differentiation potential. They 
can migrate on a substrate by generating cycles of weak 
adhesion, traction, movement, and detachment. At the end 
of the migration phase, like osteoblasts, mesenchymal–
osteoprogenitor cells adhere to the substrate by developing 
strong focal adhesion with substrates in order to start international Journal of Nanomedicine 2006:1(3) 325
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their differentiation phase. The migration and adhesion of 
bone cells in general are mediated via integrins which are 
transmembrane proteins (Anselme 2000). Among the integrin 
superfamily, fibronectin and vitronectin are proteins involved 
in osteoblasts adhesion on biomaterials in vitro (El-Ghannam 
et al 1999; Anselme 2000). Regarding their interaction with 
calcium phosphates, osteoblasts are intimately in contact 
with calcium phosphate surfaces thanks to the production 
of extracellular collagen firmly attached perpendicular or 
parallel to the substrate (Annaz et al 2004b). 
The osteogenic differentiation phase comprises three 
principal biological periods: cellular proliferation, cellular 
maturation, and matrix mineralization. Through these 
periods, the osteoblasts are known to synthesize and secrete 
subsequently type I collagen, alkaline phosphatase, and 
other non-collagenous extracellular bone matrix proteins 
such as osteocalcin, osteopontin, osteonectin, and bone 
sialoprotein. Type I collagen is expressed during the initial 
period of proliferation and extracellular matrix biosynthesis, 
whereas alkaline phosphatase is expressed during the post-
proliferative period of extracellular matrix maturation, and   
the expression of osteopontin, osteocalcin, and bone 
sialoprotein occurs later during the third period of 
extracellular-matrix mineralization (Sodek and Cheifetz 
2001). Consequently, because there is no specific single 
marker for osteoblasts, the cellular expression of a range 
of non-collagenous and collagenous proteins as well as 
alkaline phosphatase and Cbfa1 has to be investigated, when 
examining osteoblastic differentiation. Finally, osteoblasts 
participate actively to the biomaterial mineralization (Radin 
et al 1998) by producing calcium phosphate containing 
vesicles (Annaz et al 2004b). In practice, the mineralization 
of osteoblasts cannot be assayed on calcium phosphates 
biomaterials because of the similarities in composition 
between the substrate and the extracellular mineral. 
Several calcium phosphate parameters can affect the 
cellular activity: 
(i) Dissolution. Depending on the calcium phosphate 
reactivity (ie, dissolution–precipitation behavior) osteoblast 
function can be affected, in their proliferation, their 
differentiation, and their maturation phenotypes (de Bruijn 
et al 1992a, 1994b; Midy et al 2001; Knabe et al 2004; 
Siebers et al 2004; Wang et al 2004; Arinzeh et al 2005; 
Berube et al 2005). De Bruijn et al demonstrated a clear link 
between dissolution rate and early bone formation in vivo 
and the osteogenic differentiation in vitro of osteoprogenitor 
cells, suggesting therefore the influence of free calcium 
and inorganic phosphates on bone formation (de Bruijn 
et al 1992a, 1994b). As explained earlier the calcium and 
phosphate concentrations of the environment may increase 
or decrease when calcium phosphate ceramics are immersed. 
This level of modification induced by immersing calcium 
phosphate ceramics can even induce cell death (Hyakuna 
et al 1989). Changes of calcium or phosphate contents in 
culture medium also affect directly the osteoblastic activities   
(Bellows et al 1992; Meleti et al 2000; Adams et al 
2001; Dvorak et al 2004). As a consequence of surface 
transformation the cellular activity might be further affected 
as the substrate has significantly changed (Anselme et al 
1997);
(ii) Composition. A change in calcium to phosphorus ratio 
in the bioceramics means a change in phase composition 
and consequently a direct effect on the ionic exchanges 
mechanisms, as discussed earlier. The incorporation of 
mineral ions such as zinc (to a certain extent) or silicate 
in calcium phosphate bioceramics showed an increase of 
osteoblasts attachment and proliferation (Ishikaw et al 
2002; Thian et al 2005). While the presence of carbonate 
in the apatitic network of the biomaterial had contradictory 
effects on osteoblastic proliferation and alkaline phosphatase 
production compared with the HA substrate (Anselme et al 
1997; Redey et al 2000; Midy et al 2001);
(iii) Topography. On one hand, grooved calcium phos-
phate surfaces influence the osteoblastic guidance, and the 
groove profile independently of nature of the substrate (Lu 
and Leng 2003). On the other hand, in contact with micro- 
and macroporous calcium phosphate ceramic osteoblasts 
sense the surface microporosity and they can bridge even 
large pores many times larger than fully flattened osteoblasts 
(Annaz et al 2004a). For osteoblasts differentiation, Chou et 
al have demonstrated in vitro that MC3T3 cells were sensitive 
to the crystal shape: large apatite crystals induced more bone 
sialoprotein and osteocalcin expression after 3 weeks of 
culture than small apatite crystals (Chou et al 2005b). 
(iv) Surface energy. The study by Redey et al (2000) 
showed that the surface energy strongly affected the initial 
osteoblastic activity for proliferation and function, while at a 
later time the less favorable surface exhibited a comparable 
osteoblastic activity to the most favorable surface.
Calcium-phosphates – osteoclasts
Heymann et al (1999) have extensively addressed the 
cellular degradation of calcium phosphate ceramics in 
vitro and in vivo. After colonization of the substrate by 
monocytes–macrophages that are recruited during the 
inflammatory reaction following surgery (Basle et al 1993; international Journal of Nanomedicine 2006:1(3) 326
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Heymann et al 1999), osteoclasts are responsible for bone 
mineral degradation, ie, bone resorption. It has been observed 
that osteoclasts degrade calcium phosphate ceramics in a 
similar way to bone mineral: osteoclasts attach firmly to the 
substrate sealing zone. In the center of this sealing zone, they 
secrete H
+ leading to a local pH=4–5. In vivo, osteoclasts 
participate partially in the degradation of calcium phosphate 
ceramics (Gauthier et al 1999; Lu et al 2002; Ooms et al 
2002; Wenisch et al 2003; Zerbo et al 2005). In contact with 
osteoclasts, implanted bioceramics exhibited resorption pits 
associated with newly formed bone (Gauthier et al 1999; 
Ooms et al 2002; Wenisch et al 2003). However, the in vivo 
degradation of calcium phosphate materials is also associated 
with a dissolution phenomenon (Gauthier et al 1999; Lu et 
al 2002). The osteoclastic activity versus dissolution process 
of a calcium phosphate ceramic depends on the nature of the 
calcium phosphate (such as, cement, bulk ceramic, particles, 
highly soluble TCP, sparingly soluble HA) (Gauthier et al 
1999; Lu et al 2002). In the the degradation of highly soluble 
TCP ceramics in vivo, Zerbo et al (2005) have shown that 
physicochemical dissolution took place to a larger extent than 
osteoclastic resorption. Osteoclasts can also degrade calcium 
phosphates by phagocytic processes, ie, incorporation in the 
cytoplasm of the cell and thereafter dissolved by acid attack or 
enzymatic process when biomaterials particles are generated 
as the result of either local dissolution at grain boundaries or 
by mechanical stress generating debris (Heymann et al 1999). 
The osteoclastic activity is usually determined by a specific 
osteoclastic enzyme (tartrate-resistant acid phosphatase) 
depends on intrinsic properties of the calcium phosphate 
ceramics that can vary from study to stud. However, some 
general trends can be outlined: 
(i) Physicochemical dissolution kinetics of the bio-
material: calcium phosphate ceramics do not all interact 
in the same way with osteoclasts. The release of calcium 
ions from the biomaterial seems to play a critical role in 
the osteoclastic activity; above a critical range of calcium 
ions levels, osteoclastic resorption is inhibited (de Bruijn 
et al 1994a; Yamada et al 1997; Doi et al 1999). Together 
with the dissolution behavior, the structure of the calcium 
phosphate ceramic and the crystallinity influence the 
osteoclastic activity (de Bruijn et al 1994a; Yamada et al 
1997; Leeuwenburgh et al 2001). 
(ii) Carbonates and other mineral ions: carbonated apatitic 
salts, eg dentin, bone mineral, synthetic carbonated apatite, 
and calcium carbonate structures (ie aragonite, calcite), 
are resorbed by osteoclasts. It has been proposed that the 
carbonate content may stimulate the carbonic anhydrase 
activity known to promote the osteoclastic acidic secretion 
in vitro (Doi et al 1999; Leeuwenburgh et al 2001). On 
the other hand, zinc and fluoride included in calcium 
phosphate biomaterials have shown also an inhibiting effect 
on osteoclastic resorption in vitro (Sakae et al 2000; Ito 
et al 2002) and in vivo (Kawamura et al 2003; Sakae et al 
2003) for specific concentration in zinc-containing calcium 
phosphates; 
(iii) Surface energy of the calcium phosphate biomaterial: 
the polar component of the surface energy was found to 
modulate the osteoclastic adhesion in vitro. However, the 
further spreading and resorption was not influenced by 
surface energy considerations (Redey et al 1999); 
(iv) Surface roughness is known in general to influence 
the cell attachment in vitro and it was shown also in vitro 
for osteoclast attachment. Rough apatitic surfaces appear to 
enhance osteoclastic attachment compared with smooth ones 
(Gomi et al 1993).
Future directions in cell–calcium phosphate 
interactions
Cell sources At present, the reactivity of calcium phosphate 
substrates is evaluated from primary osteoblasts, osteosarcoma 
cell lines, pre-osteoblasts, and osteoprogenitor cells. Although 
human osteoprogenitor cells seem to be the most adapted for 
bone tissue engineering, very few reports deal with the culture 
of human osteoprogenitor cells. These cells are donor- and 
culture-dependent (Mendes et al 2002) and their pluripotency 
decreases with passage numbers. Unless many donors’ cells 
are used to screen calcium phosphate biomaterials, human 
osteoprogenitor cells are not a handy tool for understanding 
their interactions with calcium phosphate, as another donor’s 
cell may act very differently. To our knowledge, no extensive 
studies on different human osteoprogenitor cells have been 
performed in general on biomaterials. On the other hand, cell 
lines giving more reproducible results are “manipulated” and 
may not represent the real situation, as different cell lines have 
demonstrated a variation in responsiveness when cultured on 
a similar calcium phosphate materials (Rochet et al 2003). 
Embryonic stem cells are also a potential source in tissue 
engineering and they are investigated on calcium phosphate 
biomaterials (Both et al 2005; Melville et al 2006). 
The question remains open of which cell type to focus on 
to understand the cell–calcium phosphate interactions for a 
tissue engineering approach. 
Co-culture systems, ie, culturing two types of cells, 
are the new center of interest in the domain of bone tissue 
engineering. For example, bone tissue-engineered constructs international Journal of Nanomedicine 2006:1(3) 327
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lack viability due to insufficient vascularization. As 
angiogenesis in the bone marrow is closely associated with 
osteogenesis in developing and mature bone, co-cultures 
of osteoprogenitor cells with endothelial cells are initiated 
in order to create simultaneously vascularization and bone 
formation. However, to our knowledge there are no reports 
including the influence of a calcium phosphate biomaterial 
(or any other biomaterial) with osteoprogenitor–endothelial 
cell co-cultures. This should be taken into account in future, 
as it was shown that a calcium phosphate substrate, in 
contact with a hematopoietic–osteoblasts co-culture system, 
induced a entirely specific differentiation pathway than tissue 
culture-treated plastic (Rochet et al 2002). Could the prior 
osteoclastic resorption of the calcium phosphate biomaterial 
influence the osteoblastic activity as observed in natural bone 
remodeling?
Finally, live observation of transgenic luminescent cell 
cultures offers great opportunities to evaluate long-term 
activities on the same sample in vivo and in vitro (Cao et 
al 2005; Kotobuki et al 2005; de Boer et al 2006). More 
specifically for bone, de Boer et al has recently addressed the 
application of transgenic luminescent cell cultures coupled 
with osteogenic reporters (de Boer et al 2006). 
Limitations of in vitro tests Calcium phosphates are 
reactive and their reactivity depend on their characteristics 
(such as composition, dissolution, sintering temperature, 
microstructure). As a consequence, the calcium and phos-
phate levels in the cell culture medium can vary substantially 
without being regulated and this can affect cellular function 
(Bellows et al 1992; Meleti et al 2000; Adams et al 2001; 
Midy et al 2001; Dvorak et al 2004; Wang et al 2004; 
Arinzeh et al 2005; Berube et al 2005); while in vivo, these 
variations are automatically and rapidly regulated. Therefore 
the in vitro predictability of the biomaterial as such is often 
inconclusive (Habibovic et al 2005a). In the context of bone 
tissue engineering, scaffolds and cells are in contact in vitro 
for several days before being implanted, hence testing the in 
vitro cellular activity remains pertinent. However, Kruyt et 
al (2004) did not find any differences in vivo between the 
bone tissue engineering constructs cultured in stimulating 
or non-stimulating osteogenic differentiation medium for 6 
days, while they measured a significant difference in alkaline 
phosphatase activity in vitro between these two conditions. 
On the other hand, the number of biological assays increases 
with time, but they are still in the developmental stage. 
It is sometimes difficult to understand the regulations of 
some proteins as reported by Chou et al (Chou et al 2005a, 
2005b). The quantification of alkaline phosphatase activity 
is the most common and straightforward biological assay 
performed on osteogenic differentiation, but the presence 
of inorganic phosphate may inhibit the production by the 
cells of alkaline phosphatase activity without inhibiting the 
further mineralization process by osteoblasts (Bellows et 
al 1992). So measuring alkaline phosphatase activity as a 
unique differentiation assay on reactive calcium phosphate 
bioceramics may not represent a valid quantification of 
osteogenic differentiation. 
Relevance of calcium phosphates 
for bone tissue regeneration
Bone-bonding ability
Ionic exchange phenomena occurring with calcium 
phosphate bioceramics are associated with reactivity towards 
bone bonding, ie, the formation of an interfacial mineralized 
layer between bioceramics and bone tissue that insures their 
cohesion. Structurally, this layer is comparable to the films 
grown in vitro by dissolution–precipitation mechanisms, ie, 
nanocrystals of carbonated apatite in simulated body fluids 
that mimic the mineral composition of blood plasma. When 
formed in the presence of osteogenic cells experiments, 
this mineralized layer is comparable with the cement lines 
synthesized in vivo (de Bruijn et al 1995; Davies 1996). In   
vivo (osseous and non-osseous environment), physico-
chemical, and crystallographic continuity are observed 
between the calcium phosphate implant and the newly formed 
mineralized layer (Daculsi et al 1989; de Bruijn et al 1992b; 
Neo et al 1993). Its occurrence and thickness are related 
to the reactivity (dissolution–precipitation) of the calcium 
phosphate substrate (Neo et al 1993), the so-called bioactivity 
(Hench and Wilson 1984). This mineralized interface insures 
a physicochemical and mechanical cohesion between the 
implant and the host bone. It is particularly relevant for 
load-bearing applications, ie, hip metallic prostheses coated 
with calcium phosphate which undoubtedly improves the 
mechanical stability of the implant by augmenting and 
accelerating the bone apposition (Geesink et al 1987; Dhert 
et al 1993; Rahbek et al 2004).  
Osteoinduction by calcium phosphates 
Osteoinductive materials are biomaterials that have intrinsic 
properties to induce bone formation in a non-osseous 
environment. Recently, it has been demonstrated in goats, that 
osteoinductive macroporous calcium phosphates stimulate 
more bone formation as tissue-engineered constructs international Journal of Nanomedicine 2006:1(3) 328
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ectopically (Kruyt et al 2004) and as such in critical-sized 
orthopedic defect models (Habibovic et al 2005b). Although 
the mechanism of osteoinduction remains unclear, the ionic 
exchanges properties of the calcium phosphate scaffolds 
with the surrounding milieu have been pointed out as a 
relevant parameter, among others (Yuan et al 2001). By 
implanting intramuscularly in goats two macroporous 
calcium phosphate scaffolds identical in composition, 
crystallinity, and porosity but with different microporosities, 
Habibovic et al (2005a) have demonstrated that an elevated 
microporosity was responsible for ectopic bone formation. 
This high microporosity is directly correlated with the 
exposed surface, and therefore an elevated dissolution in the 
pores where the level of stable critical level of free calcium 
ions and possibly free orthophosphate ions might trigger cell 
differentiation into osteogenic lineage. In addition, through 
a dissolution–precipitation process, the development of a 
bone-like mineral layer might initiate bone formation either 
by mimicry with the bone mineral structure or by the presence 
of osteogenic compounds (for example bone morphogenetic 
proteins, BMPs) contained naturally in body fluids that 
might have concentrated at the newly formed mineral layer 
(Ripamonti 1996). 
Tailoring the resorption kinetics of 
calcium phosphates 
In large defects that cannot be healed naturally by bone, 
adjusting the degradation kinetics of the calcium phosphate 
bone filler with the kinetics of bone formation rate remains 
a great challenge in bone tissue regeneration. While 
contributing to bone formation, the scaffold should degrade in 
a controlled fashion to leave gradually more space for newly 
formed bone until full tissue regeneration. Mixing at various 
ratios a low soluble phase (HA) with a highly soluble phase 
(amorphous TCP) resulting in biphasic calcium phosphates 
ceramics (BCP), including additives (magnesium, carbonate, 
fluoride) in a given crystalline phase, or selecting different 
calcium phosphate phases (amorphous, DCPD, OCP, HA, 
TCP), are the options to tailor the degradation kinetics of 
calcium ceramics from a few weeks to a few years. In theory 
and in practice, one can change the resorption kinetics 
of calcium phosphate ceramics; however, no universal 
degradable scaffolds have been developed yet, and their 
degradation properties should be designed depending on 
their application. Below, two types of degradation patterns 
are described, one for load-bearing and non-load bearing 
applications.
Load-bearing applications
Calcium phosphate applied as coatings on metallic prostheses 
have a highly successful clinical record for hip arthroplasty 
(Epinette and Manley 2004). These coatings significantly 
accelerate bone growth onto the metallic implant, improve 
fixation of the implants, and extend the prostheses’ longevity. 
Extensive animal studies have been conducted taking into 
account bone formation rate versus resorption rate and 
mechanical stability. By changing the coating’s parameters 
(technique, temperature, composition) one can change the 
coatings’ degradation characteristics. For hip prostheses, the 
calcium phosphate coatings’ resorption kinetic has a certain 
paradigm. On the one hand, soluble coatings enhance bone 
formation at the early implantation stage, inducing a fast 
early fixation, but soluble coatings may lead to a second 
stage mechanical instability between the metallic implant and 
the surrounding bone. On the other hand, insoluble coatings 
delay bone fixation, ie, the first stage mechanical stability, 
but insoluble coatings stabilize the long-term fixation of the 
implant with the surrounding tissues (Dhert et al 1993, 1998; 
de Bruijn et al 1994b; Rahbek et al 2004).  
Non-load bearing applications 
In non-loading situations, bare calcium phosphates are 
used as granules or cement. Their composition can have 
virtually limitless variations with regard to their structure, 
the incorporation of additives, and the mixture of phases. 
The current scaffolds either degrade too fast (and therefore 
do not allow sufficient stability for new bone formation), or 
scaffolds do not resorb fully (and remain encapsulated by 
the newly formed bone, avoiding the entire restoration of 
natural bone mechanical strength). A common way to tune 
the degradation properties of calcium phosphate scaffolds is 
to combine a highly soluble phase (TCP) with a non-soluble 
phase (HA), to create so called BCP ceramics (Legeros et 
al 2003). Depending on the HA/TCP ratio, bone formation 
versus biomaterial resorption can be significantly improved 
or decreased (Schopper et al 2005). 
Functionalization of calcium phosphates 
for triggering bone regeneration
In view of the dissolution properties of calcium phosphate, 
several groups have used calcium phosphate ceramics as 
delivery systems by (i) adsorption on powder followed by 
compaction, (ii) co-precipitation, or (iii) adding the cement 
paste applied in bone regeneration and related fields of 
gene therapy (Shen et al 2004), or local drug delivery (Urist 
et al 1987; Lebugle et al 2002; Stigter et al 2004; Kroese-international Journal of Nanomedicine 2006:1(3) 329
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Deutman et al 2005; Liu et al 2005). For stimulation of bone 
regeneration, specific proteins have been administrated via 
calcium phosphate carriers. Bone morphogenic proteins 
(BMP, especially BMP-2) adsorbed onto ceramics (Urist 
et al 1987; Kroese-Deutman et al 2005) or co-precipitated 
into biomimetic carbonated apatite coatings (Liu et al 2005) 
induce more bone formation than ceramics alone in vivo. 
Recently, incorporation of silicate and zinc ions, in TCP and 
HA ceramics respectively, were reported to have a significant 
influence on osteogenesis in vitro and in vivo (Kawamura et 
al 2000; Ikeuchi et al 2003; Porter et al 2004b).
Conclusion and future 
perspectives
Calcium phosphates have intrinsic properties that stimulate 
bone regeneration. However, at present, their stimulating 
mechanisms remain insufficiently understood. The potential 
of the nanotechnologies applied in tissue regeneration has 
been demonstrated in different ways, eg, (i) the incorporation 
of luminescent genes in cells and animals (Cao et al 2005; 
de Boer et al 2006), allowing live molecular imaging and 
therefore the follow up on several time points on one animal 
and one type of biomaterials; (ii) the micro-arraying of 
biomaterials at the nano-liter scale (Anderson et al 2004) 
rendering possible the screening of thousands of relevant 
biomaterials in a significantly reduced amount of time, 
consumables and facilities; (iii) the surface nanotopography-
regulating cell differentiation (McBeath et al 2004). Further 
developments of the nanotechnologies applied in the fields 
of biomaterials, and cellular and molecular biology will 
facilitate closer insights and more profound understandings 
at the cell–biomaterial interaction levels. Thanks to the 
contributions from nanotechnology, we can therefore expect 
breakthroughs in the development of novel biomaterials and 
scaffolds for treating bone defects more efficiently. 
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